Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ByAinvest
Tuesday, Dec 2, 2025 4:15 pm ET1min read
IRD--
Opus Genetics has announced the approval of equity awards under its 2021 Inducement Plan, which will grant options to purchase 124,000 shares of the company's common stock to two non-executive employees. The options will vest over a four-year period, with 25% vesting after one year and the remaining 75% vesting quarterly. The awards were made to attract new talent to the company, which is developing gene therapies for inherited retinal diseases and small molecule therapies for other ophthalmic disorders.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet